MedTrace Logo

Tubular Function in Asian-American Patients Receiving TDF or ETV for HBV Treatment

NCT01715987 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 48

Last updated 2017-09-06

No results posted yet for this study

Summary

Nucleotide anti-viral analogues, including adefovir and TDF, have demonstrated kidney toxicity in HIV/HBV co-infected patients and HBV mono-infected European patients. Investigators suspected similar kidney proximal tubular injury can also occur in HBV mono infected Asian patients receiving TDF treatment.

Conditions

Interventions

DRUG

Tenofovir Disoproxil Fumarate

300mg, oral daily for two years

DRUG

Entecavir

0.5mg oral daily for two years.

Sponsors & Collaborators

  • New Discovery LLC

    lead INDUSTRY

Principal Investigators

  • Calvin Q Pan, M.D. · Mount Sinai School of Medicine, New York

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-10-31
Primary Completion
2016-05-31
Completion
2016-05-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01715987 on ClinicalTrials.gov